Dude, your one of the fellas with Gene
Logic, right? Go to vcall.com
(Jan 23 Informed Investors, room A afternoon--
about two-thirds into the tape...)
There you can hear the presentation made by
Dr. Michael Brannon (sp?), it was a good
talk--even for those of us who don't happen
to own glgc. I took a couple pages of notes,
and these questions that came to me I circled:
Does GLGC have large tissue bank?
Who makes their flow-thru chips?
GLGC says they can help big pharma
make "a sensible prioritization for
pharma" and that this is all more predictive
than animal studies--do you think that broad
comment is overstated--it seems to me that if
you have a lead from animal models you have
made it a lot farther than screening diseased
tissue--that is, if a company has a lead now
heading into clinicals, and glgc screens and
finds another target molecule for the
same indication, which would you put your
money on?--The company with the lead alredy,
the customer of glgc who gets the new lead,
or glgc which has a different business model
entirely?
Any pathologists on SI we could get to comment
on this stuff, I mean, mouse tissue is not that
different from human tissue--but I know my liver
does not look anything like somebody with hep C.
**I guess the right question is really how does
gene switching and disease relate--a newbie
question for sure, but I'm asking!** For instance,
I wonder why my asthma is switched on, and yet
there is no propensity to have asthma in my
family. Maybe examining lots of asthmatics lung
tissue wont give you any answers? Just for an
example.
I just typed all that in real fast, hope I
managed to communicate something.
Oh, I should say that GLGC is certainly on
my genomic/bioinformatics watch list now,
but there might be a couple others that
I'm closer to buying--I always have to
bottomfish you know, and you probably can
guess which ones that always come to mind.
--Mike |
